

Unchalee Permsuwan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5702384/publications.pdf>

Version: 2024-02-01

35
papers

515
citations

759233

12
h-index

713466

21
g-index

35
all docs

35
docs citations

35
times ranked

719
citing authors

#	ARTICLE	IF	CITATIONS
1	Hepatotoxicity of Nonsteroidal Anti-Inflammatory Drugs: A Systematic Review of Randomized Controlled Trials. <i>International Journal of Hepatology</i> , 2018, 2018, 1-13.	1.1	79
2	Efficacy and safety of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 112, 113-125.	4.4	51
3	Anticoagulation control of pharmacist-managed collaborative care versus usual care in Thailand. <i>International Journal of Clinical Pharmacy</i> , 2012, 34, 105-112.	2.1	43
4	Relationship of medication adherence and quality of life among heart failure patients. <i>Heart and Lung: Journal of Acute and Critical Care</i> , 2019, 48, 105-110.	1.6	42
5	Cost-utility analysis of add-on dapagliflozin treatment in heart failure with reduced ejection fraction. <i>International Journal of Cardiology</i> , 2021, 322, 183-190.	1.7	31
6	Cost-Effectiveness Analysis of Sacubitril-Valsartan Compared with Enalapril in Patients with Heart Failure with Reduced Ejection Fraction in Thailand. <i>American Journal of Cardiovascular Drugs</i> , 2018, 18, 405-413.	2.2	24
7	Cost-effectiveness of pharmacist-participated warfarin therapy management in Thailand. <i>Thrombosis Research</i> , 2013, 132, 437-443.	1.7	23
8	An updated cost-effectiveness analysis of pneumococcal conjugate vaccine among children in Thailand. <i>Vaccine</i> , 2019, 37, 4551-4560.	3.8	20
9	Cost-Effectiveness Analysis of Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Thai Patients With Non-Valvular Atrial Fibrillation. <i>Heart Lung and Circulation</i> , 2020, 29, 390-400.	0.4	20
10	Handling time in economic evaluation studies. <i>Journal of the Medical Association of Thailand = Chotmaihet Thangphaet</i> , 2014, 97 Suppl 5, S50-8.	0.1	16
11	Cost-effectiveness analysis of pharmacogenetic-guided warfarin dosing in Thailand. <i>Thrombosis Research</i> , 2014, 134, 1278-1284.	1.7	14
12	Cost-utility and budget impact analyses of gefitinib in second-line treatment for advanced non-small cell lung cancer from Thai payer perspective. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2012, 8, 53-61.	1.1	13
13	Cost-Utility Analysis of Sacubitril-Valsartan Compared with Enalapril Treatment in Patients with Acute Decompensated Heart Failure in Thailand. <i>Clinical Drug Investigation</i> , 2021, 41, 907-915.	2.2	13
14	Cost-Utility Analysis of Combination Empagliflozin and Standard Treatment Versus Standard Treatment Alone in Thai Heart Failure Patients with Reduced or Preserved Ejection Fraction. <i>American Journal of Cardiovascular Drugs</i> , 2022, 22, 577-590.	2.2	12
15	Cost-effectiveness of dipeptidyl peptidase-4 inhibitor monotherapy versus sulfonylurea monotherapy for people with type 2 diabetes and chronic kidney disease in Thailand. <i>Journal of Medical Economics</i> , 2017, 20, 171-181.	2.1	11
16	Effects of pharmacist interventions on heart failure outcomes: A systematic review and meta-analysis. <i>JACCP Journal of the American College of Clinical Pharmacy</i> , 2021, 4, 871-882.	1.0	11
17	Validation of the Thai QOL-AD version in Alzheimer's patients and caregivers. <i>Australasian Medical Journal</i> , 2014, 7, 251-259.	0.1	10
18	Long-Term Cost-Effectiveness of Insulin Glargine Versus Neutral Protamine Hagedorn Insulin for Type 2 Diabetes in Thailand. <i>Applied Health Economics and Health Policy</i> , 2016, 14, 281-292.	2.1	10

#	ARTICLE	IF	CITATIONS
19	Cost-Utility Analysis of Dapagliflozin as an Add-on to Standard of Care for Patients with Chronic Kidney Disease in Thailand. <i>Advances in Therapy</i> , 2022, 39, 1279-1292.	2.9	10
20	Cost-effectiveness of insulin detemir versus insulin glargine for Thai type 2 diabetes from a payer's perspective. <i>Journal of Medical Economics</i> , 2017, 20, 991-999.	2.1	9
21	Treatment Costs for Patients with Chronic Kidney Disease Who Received Multidisciplinary Care in a District Hospital in Thailand. <i>ClinicoEconomics and Outcomes Research</i> , 2020, Volume 12, 223-231.	1.9	6
22	Epidermal Growth Factor Receptor Mutation Testing in Thailand: A Cost-Utility Analysis. <i>Value in Health Regional Issues</i> , 2014, 3, 39-43.	1.2	5
23	Cost-Effectiveness Analysis of Fondaparinux vs Enoxaparin in Non-ST Elevation Acute Coronary Syndrome in Thailand. <i>Heart Lung and Circulation</i> , 2015, 24, 860-868.	0.4	5
24	Crizotinib treatment for advanced non-small-cell lung cancer patients: a budget impact analysis based in Thailand. <i>Current Medical Research and Opinion</i> , 2017, 33, 955-961.	1.9	5
25	Cost-Effectiveness Analysis of the Adjunctive Therapy of Ivabradine for the Treatment of Heart Failure with Reduced Ejection Fraction. <i>ClinicoEconomics and Outcomes Research</i> , 2019, Volume 11, 767-777.	1.9	5
26	Cost-Utility Analysis of First-Line Pemetrexed Plus Cisplatin in Non-Small Cell Lung Cancer in Thailand. <i>Value in Health Regional Issues</i> , 2020, 21, 9-16.	1.2	5
27	Cost-Utility Analysis of Dapagliflozin as an Add-On to Standard Treatment for Patients with Type 2 Diabetes and High Risk of Cardiovascular Disease in Thailand. <i>Diabetes Therapy</i> , 2021, 12, 1947-1963.	2.5	5
28	Economic Burdens for Treatment of Patients With Type 2 Diabetes in North Thailand: A Hospital-Based Observational Study. <i>Frontiers in Endocrinology</i> , 2022, 13, .	3.5	5
29	Cost-benefit comparison of liraglutide and sitagliptin in the treatment of type 2 diabetes in Thailand. <i>ClinicoEconomics and Outcomes Research</i> , 2019, Volume 11, 423-430.	1.9	2
30	The affordability of adding a direct-acting oral anticoagulant to the national list of essential medicine for patients with non-valvular atrial fibrillation in Thailand: a budget impact analysis. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2022, 22, 93-100.	1.4	2
31	Cost-effectiveness analysis of pharmacist interventions in patients with heart failure in Thailand. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2021, , .	1.5	2
32	Economic Evaluation of Oral Nucleos(t)ide Analogues for Patients with Chronic Hepatitis B in Thailand. <i>Applied Health Economics and Health Policy</i> , 2022, 20, 587-596.	2.1	2
33	Transcatheter aortic valve implantation in patients with severe symptomatic aortic valve stenosis: systematic review of cost-effectiveness analysis. <i>European Journal of Health Economics</i> , 0, , .	2.8	2
34	Biphasic insulin aspart 30 treatment for people with type 2 diabetes: a budget impact analysis based in Thailand. <i>Current Medical Research and Opinion</i> , 2018, 34, 369-375.	1.9	1
35	Cost-Effectiveness of Cardiac Resynchronization Therapy in Patients with Heart Failure in Thailand. <i>ClinicoEconomics and Outcomes Research</i> , 2020, Volume 12, 579-588.	1.9	1